Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.
Identifieur interne : 000527 ( Main/Exploration ); précédent : 000526; suivant : 000528Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.
Auteurs : Jason Ho [États-Unis] ; Susan Moir ; Wei Wang ; Jacqueline G. Posada ; Wenjuan Gu ; Muhammad T. Rehman ; Robin Dewar ; Colin Kovacs ; Michael C. Sneller ; Tae-Wook Chun ; Dean A. Follmann ; Anthony S. FauciSource :
- AIDS (London, England) [ 1473-5571 ] ; 2011.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Adulte, Femelle, Grippe humaine (), Grippe humaine (immunologie), Humains, Lymphocytes B (immunologie), Maryland, Mâle, Mémoire immunologique, Numération des lymphocytes CD4, Ontario, Pandémies, Sous-type H1N1 du virus de la grippe A (immunologie), Vaccination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Vaccins antigrippaux.
- immunologie : Grippe humaine, Lymphocytes B, Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux.
- Adulte, Femelle, Grippe humaine, Humains, Maryland, Mâle, Mémoire immunologique, Numération des lymphocytes CD4, Ontario, Pandémies, Vaccination.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adult, B-Lymphocytes (immunology), CD4 Lymphocyte Count, Female, Humans, Immunologic Memory, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male, Maryland, Ontario, Pandemics, Vaccination.
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Influenza Vaccines.
- geographic : Maryland, Ontario.
- immunology : B-Lymphocytes, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human.
- prevention & control : Influenza, Human.
- Adult, CD4 Lymphocyte Count, Female, Humans, Immunologic Memory, Male, Pandemics, Vaccination.
Abstract
OBJECTIVE
To assess the humoral immune response to low-dose AS03-adjuvanted and standard-dose nonadjuvanted 2009 pandemic H1N1 influenza A vaccine in HIV-infected aviremic individuals receiving antiretroviral therapy and in uninfected individuals.
DESIGN
A three-arm study.
SETTING
Two clinics: one at the National Institutes of Health in Bethesda, Maryland, USA; and the other at the Maple Leaf Medical Clinic in Toronto, Ontario, Canada.
PARTICIPANTS
HIV-infected and HIV-uninfected adults.
INTERVENTION
Single intramuscular 15 μg dose of the monovalent inactivated 2009 pandemic H1N1 influenza A vaccine without adjuvant or 3.75 μg dose of the same strain with adjuvant AS03.
MAIN OUTCOMES
Immunogenicity, as measured by hemagglutination inhibition (HAI) antibody titers and vaccine-specific memory B-cell responses.
RESULTS
A total of 74 participants were enrolled. Twenty-one HIV-infected individuals received the low-dose adjuvanted 2009 pandemic H1N1 influenza A vaccine. Twenty-nine HIV-infected and 24 HIV-uninfected individuals received the standard-dose nonadjuvanted vaccine. There were no significant differences in antibody responses at 9 weeks postvaccination among the three groups studied. However, the IgG memory B-cell response against the vaccine was significantly higher in the HIV-infected group that received the low-dose adjuvanted vaccine when compared to the HIV-infected and uninfected groups that received the standard-dose nonadjuvanted vaccine. Conclusions remained unchanged after regression adjustment for age, gender, CD4 T-cell count, and baseline HAI titer.
CONCLUSION
These data suggest that adjuvants could be used to expand coverage through dose sparing and improve humoral immune responses in immunocompromised individuals.
DOI: 10.1097/QAD.0b013e328342328b
PubMed: 21157297
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.</title><author><name sortKey="Ho, Jason" sort="Ho, Jason" uniqKey="Ho J" first="Jason" last="Ho">Jason Ho</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Moir, Susan" sort="Moir, Susan" uniqKey="Moir S" first="Susan" last="Moir">Susan Moir</name></author><author><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name></author><author><name sortKey="Posada, Jacqueline G" sort="Posada, Jacqueline G" uniqKey="Posada J" first="Jacqueline G" last="Posada">Jacqueline G. Posada</name></author><author><name sortKey="Gu, Wenjuan" sort="Gu, Wenjuan" uniqKey="Gu W" first="Wenjuan" last="Gu">Wenjuan Gu</name></author><author><name sortKey="Rehman, Muhammad T" sort="Rehman, Muhammad T" uniqKey="Rehman M" first="Muhammad T" last="Rehman">Muhammad T. Rehman</name></author><author><name sortKey="Dewar, Robin" sort="Dewar, Robin" uniqKey="Dewar R" first="Robin" last="Dewar">Robin Dewar</name></author><author><name sortKey="Kovacs, Colin" sort="Kovacs, Colin" uniqKey="Kovacs C" first="Colin" last="Kovacs">Colin Kovacs</name></author><author><name sortKey="Sneller, Michael C" sort="Sneller, Michael C" uniqKey="Sneller M" first="Michael C" last="Sneller">Michael C. Sneller</name></author><author><name sortKey="Chun, Tae Wook" sort="Chun, Tae Wook" uniqKey="Chun T" first="Tae-Wook" last="Chun">Tae-Wook Chun</name></author><author><name sortKey="Follmann, Dean A" sort="Follmann, Dean A" uniqKey="Follmann D" first="Dean A" last="Follmann">Dean A. Follmann</name></author><author><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S" last="Fauci">Anthony S. Fauci</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21157297</idno><idno type="pmid">21157297</idno><idno type="doi">10.1097/QAD.0b013e328342328b</idno><idno type="wicri:Area/Main/Corpus">000575</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000575</idno><idno type="wicri:Area/Main/Curation">000575</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000575</idno><idno type="wicri:Area/Main/Exploration">000575</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.</title><author><name sortKey="Ho, Jason" sort="Ho, Jason" uniqKey="Ho J" first="Jason" last="Ho">Jason Ho</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Moir, Susan" sort="Moir, Susan" uniqKey="Moir S" first="Susan" last="Moir">Susan Moir</name></author><author><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name></author><author><name sortKey="Posada, Jacqueline G" sort="Posada, Jacqueline G" uniqKey="Posada J" first="Jacqueline G" last="Posada">Jacqueline G. Posada</name></author><author><name sortKey="Gu, Wenjuan" sort="Gu, Wenjuan" uniqKey="Gu W" first="Wenjuan" last="Gu">Wenjuan Gu</name></author><author><name sortKey="Rehman, Muhammad T" sort="Rehman, Muhammad T" uniqKey="Rehman M" first="Muhammad T" last="Rehman">Muhammad T. Rehman</name></author><author><name sortKey="Dewar, Robin" sort="Dewar, Robin" uniqKey="Dewar R" first="Robin" last="Dewar">Robin Dewar</name></author><author><name sortKey="Kovacs, Colin" sort="Kovacs, Colin" uniqKey="Kovacs C" first="Colin" last="Kovacs">Colin Kovacs</name></author><author><name sortKey="Sneller, Michael C" sort="Sneller, Michael C" uniqKey="Sneller M" first="Michael C" last="Sneller">Michael C. Sneller</name></author><author><name sortKey="Chun, Tae Wook" sort="Chun, Tae Wook" uniqKey="Chun T" first="Tae-Wook" last="Chun">Tae-Wook Chun</name></author><author><name sortKey="Follmann, Dean A" sort="Follmann, Dean A" uniqKey="Follmann D" first="Dean A" last="Follmann">Dean A. Follmann</name></author><author><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S" last="Fauci">Anthony S. Fauci</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Adult</term><term>B-Lymphocytes (immunology)</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>Humans</term><term>Immunologic Memory</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Maryland</term><term>Ontario</term><term>Pandemics</term><term>Vaccination</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Adulte</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Humains</term><term>Lymphocytes B (immunologie)</term><term>Maryland</term><term>Mâle</term><term>Mémoire immunologique</term><term>Numération des lymphocytes CD4</term><term>Ontario</term><term>Pandémies</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Vaccination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Maryland</term><term>Ontario</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Lymphocytes B</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>B-Lymphocytes</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>Humans</term><term>Immunologic Memory</term><term>Male</term><term>Pandemics</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Maryland</term><term>Mâle</term><term>Mémoire immunologique</term><term>Numération des lymphocytes CD4</term><term>Ontario</term><term>Pandémies</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To assess the humoral immune response to low-dose AS03-adjuvanted and standard-dose nonadjuvanted 2009 pandemic H1N1 influenza A vaccine in HIV-infected aviremic individuals receiving antiretroviral therapy and in uninfected individuals.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>A three-arm study.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING</b></p><p>Two clinics: one at the National Institutes of Health in Bethesda, Maryland, USA; and the other at the Maple Leaf Medical Clinic in Toronto, Ontario, Canada.</p></div><div type="abstract" xml:lang="en"><p><b>PARTICIPANTS</b></p><p>HIV-infected and HIV-uninfected adults.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTION</b></p><p>Single intramuscular 15 μg dose of the monovalent inactivated 2009 pandemic H1N1 influenza A vaccine without adjuvant or 3.75 μg dose of the same strain with adjuvant AS03.</p></div><div type="abstract" xml:lang="en"><p><b>MAIN OUTCOMES</b></p><p>Immunogenicity, as measured by hemagglutination inhibition (HAI) antibody titers and vaccine-specific memory B-cell responses.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 74 participants were enrolled. Twenty-one HIV-infected individuals received the low-dose adjuvanted 2009 pandemic H1N1 influenza A vaccine. Twenty-nine HIV-infected and 24 HIV-uninfected individuals received the standard-dose nonadjuvanted vaccine. There were no significant differences in antibody responses at 9 weeks postvaccination among the three groups studied. However, the IgG memory B-cell response against the vaccine was significantly higher in the HIV-infected group that received the low-dose adjuvanted vaccine when compared to the HIV-infected and uninfected groups that received the standard-dose nonadjuvanted vaccine. Conclusions remained unchanged after regression adjustment for age, gender, CD4 T-cell count, and baseline HAI titer.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These data suggest that adjuvants could be used to expand coverage through dose sparing and improve humoral immune responses in immunocompromised individuals.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21157297</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.</ArticleTitle><Pagination><MedlinePgn>295-302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e328342328b</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the humoral immune response to low-dose AS03-adjuvanted and standard-dose nonadjuvanted 2009 pandemic H1N1 influenza A vaccine in HIV-infected aviremic individuals receiving antiretroviral therapy and in uninfected individuals.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A three-arm study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Two clinics: one at the National Institutes of Health in Bethesda, Maryland, USA; and the other at the Maple Leaf Medical Clinic in Toronto, Ontario, Canada.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">HIV-infected and HIV-uninfected adults.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Single intramuscular 15 μg dose of the monovalent inactivated 2009 pandemic H1N1 influenza A vaccine without adjuvant or 3.75 μg dose of the same strain with adjuvant AS03.</AbstractText><AbstractText Label="MAIN OUTCOMES" NlmCategory="RESULTS">Immunogenicity, as measured by hemagglutination inhibition (HAI) antibody titers and vaccine-specific memory B-cell responses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 74 participants were enrolled. Twenty-one HIV-infected individuals received the low-dose adjuvanted 2009 pandemic H1N1 influenza A vaccine. Twenty-nine HIV-infected and 24 HIV-uninfected individuals received the standard-dose nonadjuvanted vaccine. There were no significant differences in antibody responses at 9 weeks postvaccination among the three groups studied. However, the IgG memory B-cell response against the vaccine was significantly higher in the HIV-infected group that received the low-dose adjuvanted vaccine when compared to the HIV-infected and uninfected groups that received the standard-dose nonadjuvanted vaccine. Conclusions remained unchanged after regression adjustment for age, gender, CD4 T-cell count, and baseline HAI titer.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data suggest that adjuvants could be used to expand coverage through dose sparing and improve humoral immune responses in immunocompromised individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moir</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jacqueline G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Rehman</LastName><ForeName>Muhammad T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Dewar</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sneller</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Tae-Wook</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>Follmann</LastName><ForeName>Dean A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Fauci</LastName><ForeName>Anthony S</ForeName><Initials>AS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN261200800001C</GrantID><Acronym>RC</Acronym><Agency>CCR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261200800001E</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA AI000825-12</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261200800001E</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="Y">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008396" MajorTopicYN="N" Type="Geographic">Maryland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21157297</ArticleId><ArticleId IdType="doi">10.1097/QAD.0b013e328342328b</ArticleId><ArticleId IdType="pmc">PMC3791488</ArticleId><ArticleId IdType="mid">NIHMS517732</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2000 Jul 1;18(26):3040-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10825608</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Dec 16;116(25):5571-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20837780</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2001 Feb 12;161(3):441-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11176770</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2001 Dec;65(4):644-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11745926</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2003 Sep 8;21(25-26):3629-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12922092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1988 Sep 1;109(5):383-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2970238</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 1990 Jul;98(1):33-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2361409</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 1998 Dec 3;12(17):F217-23</Citation><ArticleIdList><ArticleId IdType="pubmed">9863863</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Mar 10;281(10):901-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10078486</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 May 1;191(9):1442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15809902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Aug 18;370(9587):580-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17707753</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2007 Sep;27(3):384-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17892847</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Nov 8;357(19):1903-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17989383</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2008 Feb;15(2):253-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18003811</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2008 Apr 15;46(8):1310-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18444872</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2008 Aug 4;205(8):1797-805</Citation><ArticleIdList><ArticleId IdType="pubmed">18625747</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Sep 1;198(5):642-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18576945</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Sep 12;26 Suppl 4:D17-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19230153</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2009 Apr;9(4):235-45</Citation><ArticleIdList><ArticleId IdType="pubmed">19319142</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2009 May 15;48(10):1402-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19361304</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2009 Jun;21(3):298-304</Citation><ArticleIdList><ArticleId IdType="pubmed">19497721</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Recomm Rep. 2009 Aug 28;58(RR-10):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19713882</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2424-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19745215</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Jan 2;375(9708):56-66</Citation><ArticleIdList><ArticleId IdType="pubmed">20018364</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Jan 22;28(4):907-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19932673</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Feb 17;28(7):1740-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20034605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Mar 27;375(9720):1100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20096450</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Microbiol Immunol. 2010 May;199(2):117-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20162304</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2010 Jun 1;24(9):F31-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20559034</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2010 Jun;22(3):411-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20466528</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2010 Jul;17(7):1055-65</Citation><ArticleIdList><ArticleId IdType="pubmed">20463105</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2010 Sep 10;24(14):2187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20616698</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2000 Aug;31(2):604-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10987729</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Chun, Tae Wook" sort="Chun, Tae Wook" uniqKey="Chun T" first="Tae-Wook" last="Chun">Tae-Wook Chun</name><name sortKey="Dewar, Robin" sort="Dewar, Robin" uniqKey="Dewar R" first="Robin" last="Dewar">Robin Dewar</name><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S" last="Fauci">Anthony S. Fauci</name><name sortKey="Follmann, Dean A" sort="Follmann, Dean A" uniqKey="Follmann D" first="Dean A" last="Follmann">Dean A. Follmann</name><name sortKey="Gu, Wenjuan" sort="Gu, Wenjuan" uniqKey="Gu W" first="Wenjuan" last="Gu">Wenjuan Gu</name><name sortKey="Kovacs, Colin" sort="Kovacs, Colin" uniqKey="Kovacs C" first="Colin" last="Kovacs">Colin Kovacs</name><name sortKey="Moir, Susan" sort="Moir, Susan" uniqKey="Moir S" first="Susan" last="Moir">Susan Moir</name><name sortKey="Posada, Jacqueline G" sort="Posada, Jacqueline G" uniqKey="Posada J" first="Jacqueline G" last="Posada">Jacqueline G. Posada</name><name sortKey="Rehman, Muhammad T" sort="Rehman, Muhammad T" uniqKey="Rehman M" first="Muhammad T" last="Rehman">Muhammad T. Rehman</name><name sortKey="Sneller, Michael C" sort="Sneller, Michael C" uniqKey="Sneller M" first="Michael C" last="Sneller">Michael C. Sneller</name><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Ho, Jason" sort="Ho, Jason" uniqKey="Ho J" first="Jason" last="Ho">Jason Ho</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000527 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000527 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21157297
|texte= Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21157297" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |